Skip to main content

Table 1 Clinical characteristics at the eight-year study visit comparing children with juvenile idiopathic arthritis with and without information on physical education (PE) and school attendance

From: Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study

Characteristics at final study visit (n = 347) Participants with information on PE or school attendance (n = 285) Participants without information on PE or school attendance (n = 62)
N n (%) or median (IQR) N n (%) or median (IQR)
Female, n (%) 285 188 (66.0) 62 39 (62.9)
Age at disease onset, years 285 5.3 (2.3–9.4) 62 8.3 (3.8–11.2)
Cumulative joint count 285 6 (2–12) 62 4 (2–10)
Active joints 285 0.0 (0.0–0.0) 62 0.0 (0.0–0.0)
Physician GA, VAS 192 0.0 (0.0–0.9) 4 0.3 (0.1–1.8)
Patient/parent GA, VAS 216 0.0 (0.0–1.2) 3 0.3 (0.0–0.5)
Pain VAS 220 0.0 (0.0–1.3) 3 0.0 (0.0–0.5)
CHAQ score 285 0.0 (0.0–0.1) 8 0.0 (0.0–0.1)
CHQ-PF50, PhS score 160 52.5 (45.5–56.9) 4 46.8 (36.2–53.9)
CHQ-PF50, PsS score 160 54.8 (48.0–59.6) 4 40.9 (32.4–46.8)
DMARDs, n (%) 285 102 (35.8) 62 8 (12.9)
Oligoarticular persistent, n (%) 285 84 (29.5) 62 25 (40.3)
Oligoarticular extended, n (%) 285 49 (17.2) 62 8 (12.9)
Polyarticular RF negative, n (%) 285 58 (20.3) 62 7 (11.3)
Polyarticular RF positive, n (%) 285 2 (0.7) 62 1 (1.6)
Systemic arthritis, n (%) 285 8 (2.8) 62 1 (1.6)
Psoriatic arthritis, n (%) 285 13 (4.6) 62 0 (0)
Enthesitis-related arthritis, n (%) 285 29 (10.2) 62 12 (19.3)
Undifferentiated arthritis, n (%) 285 42 (14.7) 62 8 (12.9)
ESR mm/hour 193 7.0 (4.0–11.0) 14 8.5 (6.0–14.0)
CRP mg/liter 201 0.0 (0.0–5.0) 12 2.5 (0.0–7.5)
RF positive, n (%) 150 5 (3.3) 29 2 (6.9)
HLA-B27 positive, n (%) 274 62 (22.6) 52 11 (21.2)
ANA positive, n (%) 284 66 (23.2) 60 13 (21.7)
  1. Values are the median (interquartile range, IQR), unless indicated otherwise. PE Physical education and school attendance assessed at the eight-year study visit, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, ANA Antinuclear antibody, assessed twice with at least 3 months interval, RF Rheumatoid factor, assessed twice with at least 3 months interval, HLA-B27 Human leucocyte antigen